Albert David Past Earnings Performance
Past criteria checks 5/6
Albert David has been growing earnings at an average annual rate of 26.1%, while the Pharmaceuticals industry saw earnings growing at 14.9% annually. Revenues have been growing at an average rate of 2.5% per year. Albert David's return on equity is 18.9%, and it has net margins of 18.7%.
Key information
26.1%
Earnings growth rate
26.1%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 2.5% |
Return on equity | 18.9% |
Net Margin | 18.7% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Albert David makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 3,548 | 662 | 909 | 0 |
30 Sep 23 | 3,411 | 581 | 881 | 0 |
30 Jun 23 | 3,403 | 579 | 886 | 0 |
31 Mar 23 | 3,416 | 362 | 890 | 0 |
31 Dec 22 | 3,345 | 366 | 926 | 0 |
30 Sep 22 | 3,316 | 340 | 927 | 0 |
30 Jun 22 | 3,256 | 266 | 936 | 0 |
31 Mar 22 | 3,135 | 353 | 935 | 0 |
31 Dec 21 | 2,959 | 384 | 911 | 0 |
30 Sep 21 | 2,895 | 365 | 906 | 0 |
30 Jun 21 | 2,748 | 337 | 828 | 0 |
31 Mar 21 | 2,474 | 221 | 887 | 0 |
31 Dec 20 | 2,507 | 116 | 942 | 0 |
30 Sep 20 | 2,650 | 107 | 954 | 0 |
30 Jun 20 | 2,829 | 88 | 976 | 0 |
31 Mar 20 | 3,208 | 192 | 994 | 0 |
31 Dec 19 | 3,285 | 299 | 1,004 | 0 |
30 Sep 19 | 3,259 | 272 | 1,015 | 0 |
30 Jun 19 | 3,141 | 198 | 1,024 | 0 |
31 Mar 19 | 3,169 | 177 | 1,013 | 0 |
31 Dec 18 | 3,160 | 179 | 1,026 | 0 |
30 Sep 18 | 3,136 | 206 | 1,001 | 0 |
30 Jun 18 | 3,271 | 287 | 993 | 0 |
31 Mar 18 | 2,874 | 135 | 971 | 0 |
31 Dec 17 | 2,976 | 76 | 1,055 | 0 |
30 Sep 17 | 2,799 | 17 | 1,065 | 0 |
30 Jun 17 | 2,784 | 4 | 1,059 | 0 |
31 Mar 17 | 2,949 | 171 | 1,003 | 0 |
31 Dec 16 | 3,008 | 103 | 1,040 | 0 |
30 Sep 16 | 3,130 | 68 | 1,029 | 0 |
30 Jun 16 | 3,165 | 70 | 840 | 0 |
31 Mar 16 | 3,226 | 72 | 987 | 0 |
31 Dec 15 | 3,229 | 81 | 1,456 | 39 |
30 Sep 15 | 3,255 | 139 | 1,441 | 39 |
30 Jun 15 | 3,236 | 146 | 1,425 | 39 |
31 Mar 15 | 3,208 | 137 | 919 | 0 |
31 Dec 14 | 3,287 | 156 | 1,296 | 43 |
30 Sep 14 | 3,161 | 136 | 1,262 | 43 |
30 Jun 14 | 3,032 | 125 | 1,221 | 43 |
31 Mar 14 | 2,898 | 126 | 1,199 | 43 |
31 Dec 13 | 2,825 | 109 | 1,118 | 25 |
30 Sep 13 | 2,727 | 92 | 1,100 | 25 |
30 Jun 13 | 2,696 | 91 | 1,095 | 25 |
31 Mar 13 | 2,641 | 86 | 1,091 | 25 |
Quality Earnings: 524075 has high quality earnings.
Growing Profit Margin: 524075's current net profit margins (18.7%) are higher than last year (10.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524075's earnings have grown significantly by 26.1% per year over the past 5 years.
Accelerating Growth: 524075's earnings growth over the past year (80.9%) exceeds its 5-year average (26.1% per year).
Earnings vs Industry: 524075 earnings growth over the past year (80.9%) exceeded the Pharmaceuticals industry 23.8%.
Return on Equity
High ROE: 524075's Return on Equity (18.9%) is considered low.